A recent study of HIV serodiscordant couples found that depot medroxyprogesterone acetate (DMPA) and oral contraceptive pills (OCPs) were associated with increased HIV risk in the presence, but not in the absence, of bacterial vaginosis. We assessed whether bacterial vaginosis is an effect modifier of the association between hormonal contraception and HIV seroconversion in female sex workers (FSWs) in Mombasa, Kenya.
Prospective cohort study.
Data collected from HIV-negative FSWs from 1993 to 2017 were analyzed. Cox proportional hazards models were used to assess the relationship between HIV seroconversion and use of DMPA, OCPs, or hormonal contraceptive implants (Norplant, Jadelle).
A total of 1985 women contributed 7127 person-years of follow-up; 307 women seroconverted to HIV (4.32/100 person-years). DMPA was significantly associated with elevated risk of HIV seroconversion in women with [aHR 1.56, 95% confidence interval (CI) 1.08–2.25; P = 0.02] and without (aHR 2.08, 95% CI 1.46–2.97; P < 0.001) bacterial vaginosis (interaction P = 0.4). Similarly, OCP use was associated with increased HIV risk both in the presence (aHR 1.50, 95% CI 0.94–2.39; P = 0.09) and absence (aHR 1.61, 95% CI 0.99–2.64; P = 0.06) of bacterial vaginosis (interaction P = 0.9), though neither stratum reached statistical significance. Implants were not associated with HIV seroconversion overall (aHR 0.99, 95% CI 0.40–2.45; P = 0.9), or in women with (aHR 0.65, 95% CI 0.16–2.72; P = 0.6) and without (aHR 1.39, 95% CI 0.43–4.46; P = 0.6) bacterial vaginosis (interaction P = 0.5).
Bacterial vaginosis had no effect on the associations between hormonal contraceptives and HIV seroconversion in this cohort. Contraceptive implants were not associated with increased HIV risk compared with no contraception.
aDepartment of Medicine
bDepartment of Global Health
cDepartment of Biostatistics
dDepartment of Epidemiology, University of Washington, Seattle, USA
eDepartment of Medical Microbiology, University of Nairobi, Nairobi, Kenya
fVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
gMaisha Consulting bvba, Belgium
hGilead Sciences, Foster City, California, USA.
Correspondence to Michelle C. Sabo, MD, PhD, University of Washington, Box 356423, 1959 NE Pacific Street, Seattle, WA 98195, USA. Tel: +1 206 543 4278; fax: +1 206 543 4818; e-mail: email@example.com
Received 23 November, 2018
Revised 15 January, 2019
Accepted 18 January, 2019
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).